{'52WeekChange': 2.3689322,
 'SandP52WeekChange': 0.0644362,
 'address1': '420 Stevens Avenue',
 'address2': 'Suite 370',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.53,
 'askSize': 1000,
 'averageDailyVolume10Day': 392250,
 'averageVolume': 1558920,
 'averageVolume10days': 392250,
 'beta': 2.064425,
 'beta3Year': None,
 'bid': 3.45,
 'bidSize': 800,
 'bookValue': 0.119,
 'category': None,
 'circulatingSupply': None,
 'city': 'Solana Beach',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.63,
 'dayLow': 3.44,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 81690152,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.2435715,
 'fiftyTwoWeekHigh': 5,
 'fiftyTwoWeekLow': 0.733,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 21640210,
 'forwardEps': -0.13,
 'forwardPE': -26.692308,
 'fromCurrency': None,
 'fullTimeEmployees': 5,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.041490003,
 'heldPercentInstitutions': 0.14522,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/evokepharma.com',
 'longBusinessSummary': 'Evoke Pharma, Inc., a specialty pharmaceutical '
                        'company, primarily focuses on the development of '
                        'drugs for the treatment of gastroenterological '
                        'disorders and diseases. It is developing Gimoti, a '
                        'metoclopramide nasal spray, which is completed Phase '
                        'III clinical trials for the relief of symptoms '
                        'associated with acute and recurrent diabetic '
                        'gastroparesis in women. The company was founded in '
                        '2007 and is headquartered in Solana Beach, '
                        'California.',
 'longName': 'Evoke Pharma, Inc.',
 'market': 'us_market',
 'marketCap': 85718024,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_35230943',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -6950698,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.5,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.29,
 'phone': '858-345-1494',
 'previousClose': 3.53,
 'priceHint': 4,
 'priceToBook': 29.159664,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.63,
 'regularMarketDayLow': 3.44,
 'regularMarketOpen': 3.5,
 'regularMarketPreviousClose': 3.53,
 'regularMarketPrice': 3.5,
 'regularMarketVolume': 242656,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24702600,
 'sharesPercentSharesOut': 0.049200002,
 'sharesShort': 1216361,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 272149,
 'shortName': 'Evoke Pharma, Inc.',
 'shortPercentOfFloat': 0.0513,
 'shortRatio': 0.35,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'EVOK',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.289,
 'twoHundredDayAverage': 1.8796978,
 'volume': 242656,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.evokepharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92075'}